Special Issue

Bladder Cancer and Personalized Treatment

Message from the Guest Editors

The integration of various "omics" technologies for investigating the genetic and genomic make-up of bladder cancer has improved our understanding of the molecular tumor biology and continues to contribute to the development of more personalized treatment approaches. Different molecular subtypes have been identified in (non)muscle invasive bladder cancer; the presence of tumor heterogeneity has been identified as a source of treatment resistance, and molecular tumor make-up is now being evaluated in different clinical studies as a predictor of treatment response. This Special Issue of the Journal of Personalized Medicine aims to highlight the current state of science and showcase some of the latest findings in the field of bladder omics. The topics include studies that investigate molecular biomarkers of response to treatment and radiomics to improve staging in muscleinvasive bladder cancer.

Guest Editors

Dr. Tahlita C. M. Zuiverloon

Dr. Markus Eckstein

Dr. Astrid A.M. van der Veldt

Deadline for manuscript submissions closed (15 March 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



mdpi.com/si/78455

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).